Skip to main content Skip to main navigation Skip to search Skip to footer

Transforming Clinical Development

Transforming Clinical Development

R&D spend has tripled, the number of new drugs approved by FDA have reduced to 30%, thus increasing the pressure on pharmaceutical industry to bring in efficiencies in every process. Site monitoring constitutes 45% of the annual Clinical Trials expenditure in the R&D spend for a typical Pharma. It is now imperative to target on-site monitoring of clinical trials by identifying centers with anomalous and inconsistent data.

Contact Us
MAX CHARACTERS: 10,000

We will treat any information you submit with us as confidential. Please read our privacy statement for additional information.

We will treat any information you submit with us as confidential. Please read our privacy statement for additional information.